BlinkAid develops a wearable application for the prevention and alleviation of Dry Eye and Computer Vision Syndromes’ burden. Taking an innovative and bold approach, leveraging novel physiological mechanisms of action, BlinkAid makes use of glasses frame as a platform. BlinkAid’s patent protected technology, embedded onto the users’ personal glasses, monitor blinks’ rate and quality to compensate for improper blinking using highly specific and personally tailored neurostimulation. In practice BlinkAid is to be the first to make use of the glasses for other medical aid other than vision correction and the first to address Dry Eye Symptoms via the natural mechanism of blinking.
Red eyes, itching and eye pain are only some of what is generally referred to as “dry eye symptoms”. To make things worse, many different causes and medical conditions are expressed in the same way making it difficult to properly address the source of the discomfort and pain. One known and dominant cause of the symptoms is the time spent in front of the computer. Studies have shown a significant decrease in blinking quality and rate among people working long hours in front of screens. Current treatments rely mainly on the use of eyedrops, posing a burden on user’s daily routine and offering limited relief.
While blinking is responsible for coating the surface of the eye with the thin and transparent tears layer, capable of compensating for the different causes of the dry eye symptoms. To date governing the blinking mechanism has been out of reach, and BlinkAid is taking on the challenge to change that.
Integrated onto users eye-glasses, BlinkAid will evoke the blinking reflex by high resolution nerve-stimulation technology. The nerves’ fibers map in the human body differs between people and even between one’s two eyes. BlinkAid will tailor the stimulation map around the eye making the use of our technology easy, comfortable and most importantly, relieving.
Yechiam Sapir, PhD, CEO
An experienced executive with a strong background in both academia and the biomedical industry, bringing expertise and a deep understanding of project management within the field of neurophysiology.
Raz Karl, B.Sc, B.Des, CTO
Internationally awarded roboticist, industrial designer & senior software engineer with 10+ years of experience developing embedded systems and cyber security solutions in elite IDF tech unit and leading Israeli startups. Alumni of the Hebrew University and Bezalel Academy
Iftach Yassur, MD, CMO
Ophthalmologist Oculoplastic specialist, Director of the Oculoplastics Department (eyelid, eye socket and tear duct surgery) at the Rabin Medical Center (Beilinson, Sharon and Schneider Pediatric hospitals). Head of the Eye Tumor Center at the Beilinson Hospital and the Davidoff Center for Cancer.
The Market Opportunity
Over 300 million people worldwide suffer from Dry Eye Disease (DED) and many more suffer from Digital Eye Strain (DES), also referred to as Computer Vision Syndrome (CVS). These numbers are expected to continue rising with the ageing of the population, and significantly with the increased use of computer screens as part of our daily life and workplaces in particular. The dry eye artificial tears market reached $4.6 Billion already and is estimated to exceed $6 Billion by 2027, offering a huge opportunity to BlinkAid and its innovative technology.